ClinicalTrials.gg
CompletedNCT06908954Updated Apr 30, 2026

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

A Phase 1 interventional study of Palovarotene and Palovarotene in Hepatic Impairment and Healthy, sponsored by Ipsen. Completed at 4 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Ipsen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function.

The study will also assess the safety and tolerability of the single dose of palovarotene.

Participants will be enrolled in stages and divided into three groups based on their liver function:

  • Group 1: Healthy participants with normal liver function
  • Group 2: Participants with moderate liver impairment
  • Group 3: Participants with severe liver impairment (only enrolled if Group 2 results are safe and acceptable)

Blood samples will be taken to assess how the drug binds to proteins in the blood. Participants will undergo various safety checks and procedures. Participants will stay in the clinical unit until Day 5 for these assessments and will return on Day 10 for a final visit.

02

Conditions studied

  • Hepatic Impairment
  • Healthy
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants must be 18 to 70 years of age (inclusive) at the time of signing .
  • Body weight at least 60.0 kg with (BMI) within the range of 18.0 and 36.0 kg/m² (inclusive), at screening. BMI of >36.0 to ≤40.0 may be eligible if participant has moderate ascites scoring 3 points on the C-P criteria.
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials
  • Clinical diagnosis of chronic hepatic disease (stable for more than 3 months) with a documented history of underlying hepatic insufficiency and no acute episodes of illness within 30 days prior to Day -1 (admission) and no significant change in disease status (i.e. up to 1 point in the C-P classification) from screening to Day -1.
  • A stable medication regimen, defined as not starting new therapy(ies) or significant changing dosage(s) within 30 days prior to dosing.

Exclusion criteria

Exclusion Criteria:

  • Presence or significant history of cardiovascular, respiratory, hepatic (except for the hepatic impairment for those concerned), renal, gastrointestinal, biliary, mucocutaneous, endocrinological, haematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study intervention, or interfering with the interpretation of data.
  • Lymphoma, leukaemia or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Breast cancer within the past 10 years.
  • Use of any medications (prescription or over the counter), herbal tea, energy drinks (including natural stimulants), herbal products (e.g. St. John's wort, garlic, milk thistle) or supplements/supratherapeutic doses of vitamins within 14 days prior to Day 1 and through discharge, apart from those approved by the investigator and the sponsor's medical monitor. Those with hepatic impairment may take concomitant medications
  • Use of any medications that are moderate or strong inhibitors or inducers of
  • Donation or loss (excluding volume drawn at screening or during menses) of more than 250 mL of blood or blood product within 3 months prior to screening. In addition, plan of blood donation within 8 weeks after the last PK sampling.
  • Presence of surface antigen (HBsAg) at screening or within 3 months prior to the dose of study intervention.
  • Positive antibody test result at screening or within 3 months prior to the dose of study intervention. Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.
  • Positive hepatitis C RNA test result at screening or within 3 months prior to the dose of study intervention. Note: Test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.
  • Sensitivity to the study intervention, or components thereof (including inactive ingredients), or drug or other allergy that, in the opinion of the investigator (or medical monitor), contraindicates participation in the study
  • Evidence of relevant active disease at screening, including gastroenterological (other than hepatic cirrhosis), cardiac (e.g. myocardial infarction in the past year, angina or congestive heart failure), renal, respiratory, haematological, neuropsychiatric or neoplastic (basal or squamous cell skin cancer is acceptable) disease.
  • Acute hepatitis B (positive for HBsAg) or acute hepatitis C (positive for anti-hepatitis C virus (HCV) for a duration of less than 6 months). Note: Participants with chronic HCV (positive for HCV RNA or anti-HCV for more than 6 months) are eligible for enrolment, if stable, as assessed by the investigator.
  • Primary sclerosing cholangitis or preliminary diagnosed biliary obstruction at screening.
  • Current or chronic history of liver disease. This includes (but is not limited to hepatitis virus infections), drug- or alcohol-related liver disease, non-alcoholic steatohepatitis, hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Group 1 Healthy participants

    Evaluation of the pharmacokinetics of IPN60120 in control healthy participants matching the age, sex and weight with hepatic impaired participants

    Drug: Palovarotene

  • Experimental
    Group 2 Moderate Hepatic impaired participants

    Evaluation of the pharmacokinetics of IPN60120 in Moderate Hepatic impaired participants (Child-Pugh class B)

    Drug: Palovarotene

  • Experimental
    Group 3 Severe Hepatic impaired participants

    Evaluation of the pharmacokinetics of IPN60120 in Severe Hepatic impaired participants (Child-Pugh class C)

    Drug: Palovarotene

Interventions

  • A single dose of maximum 10 mg of palovarotene will be administered orally on Day 1 to healthy control participants with normal hepatic function

  • A single 10 mg dose of palovarotene will be administered orally on Day 1 to Moderate hepatic impaired participants (Child-Pugh class B)

  • A single 10 mg dose of either 5 mg or 10 mg of palovarotene will be administered orally on Day 1 to Severe hepatic impaired participants (Child-Pugh class C).

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma drug concentration (Cmax)

    Measure of maximum observed plasma drug concentration (Cmax) (total and unbound) over 96 hours after dosing

    Time frame: Over 96 hours postdose

  2. Unbound fraction of drug in plasma (fu)

    Measure of maximum observed plasma drug concentration (Cmax) (total and unbound) over 96 h after dosing

    Time frame: Over 96 hours postdose

  3. Time to maximum observed plasma concentration (Tmax)

    Measure of AUC from time 0 to infinity (AUC0-∞) (total and unbound)

    Time frame: Over 96 hours postdose

  4. Area under the plasma concentration-time curve (AUC) from time 0 to infinity (AUC0-∞)

    Measure of AUC from time 0 to infinity (AUC0-∞) (total and unbound)

    Time frame: Over 96 hours postdose

  5. AUC from 0 to time t corresponding to the last quantifiable concentration (AUC0-tlast)

    Measure of AUC from 0 to time t corresponding to the last quantifiable concentration (AUC0-tlast) (total and unbound)

    Time frame: Over 96 hours postdose

  6. Apparent terminal elimination half life (T1/2)

    Measure of apparent terminal elimination half-life over 96 hours post-dose

    Time frame: Over 96 hours postdose

  7. Apparent terminal elimination rate constant (λz).

    Measure of apparent terminal elimination rate constant (λz) over 96 hours post-dose

    Time frame: Over 96 hours postdose

Secondary outcomes

  1. Percentage of participants with Adverse Events (AEs)

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From Baseline to Day 10

  2. Percentage of Participants with clinically significant changes from baseline in Laboratory Parameters

    Clinically significant change in laboratory parameters will be reported. The clinical significance will graded by the investigator.

    Time frame: At Day 2, Day 5 and Day 10

  3. Percentage of participants with clinically significant change from baseline in physical examinations

    Clinically significant changes in physical examinations will be reported. The clinical significance will be graded by the investigator.

    Time frame: At Day 1, 2 and 3, Day 5 and Day 10

  4. Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs

    Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

    Time frame: At Day 1, 2 and 3, Day 5 and Day 10

  5. Percentage of participants with clinically significant change from baseline in 12-lead Electrocardiogram (ECG) readings

    Time frame: At Day 1, 2 and 3, Day 5 and Day 10

07

Study locations

4 sites
  • ERG - Clinical Pharmacology of Miami
    Miami, Florida 33172, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation/Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Feb 2026, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 3, 2025
StartActual
Mar 14, 2025
Primary completionActual
Feb 6, 2026
CompletionActual
Feb 6, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06908954
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Mar 14, 2025
Primary completion
Feb 6, 2026
Completion
Feb 6, 2026
Last update
Apr 30, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palovarotene

Start the discussion